Halozyme Therapeutics Projects $1.7–$1.8 Billion Revenue Growth in 2026
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowHalozyme Therapeutics, Inc. (NASDAQ: HALO) announced the appointment of David Ramsay as interim CFO on March 12, 2026. The company forecasts revenues between $1.7 billion and $1.8 billion for the year, marking a projected increase of 22% to 30%. Notably, CEO Helen Torley projected royalties from the ENHANZE drug-delivery system to reach $1.1–$1.2 billion. Halozyme also has seven ENHANZE products in development and aims for 40 drugs to be approved or in development by 2028, highlighting its growth trajectory despite the ongoing patent litigation with Merck.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Merck & Co. Inc. (MRK)
Merck is a global pharmaceutical company best known for its oncology, vaccine, and animal-health franchises.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier MRK news
- Merck's Winrevair Meets Primary Endpoint in Heart Failure Trial Results
- Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals
- Merck Pursues $6 Billion Acquisition of Terns Pharma, Reports FT
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
